Abstract: A device for the treatment of esophageal atresias and stenosis comprises at least one tubular body of elongated shape intended, in use, to be inserted inside an esophagus affected by esophageal atresia and divided into a distal stump and into a proximal stump, at least one magnetic element associated with one end of the tubular body and intended to be placed at the point where either the distal stump or the proximal stump is located.

Abstract: A third generation of CAR-CD30 T cells is for treatment of CD30+ Tumors such as lymphoid malignancies, leukemia, and solid tumors. A CD30 chimeric antigen receptor includes, from the N-terminus to the C? terminus, a signal peptide, which is linked by a first linker to an anti CD30 single chain antibody domain from AC10 hybridoma including the AC10 VL sequence and the AC10 VH sequence. The AC10 VL and VH sequences are linked by a second linker.

Abstract: The present invention relates to a peptide having the sequence from N-terminus to C-terminus X-2X-1ZX1X2X3X4X5 wherein Z is tyrosine, phosphotyrosine or a non-natural analogue of phosphotyrosine, such as phosphonodifluoromethyl phenylalanine (F2Pmp) X-2 is a hydrophobic amino acid, such as Leu, Ile, Val, Phe, Tyr, Trp and Met X-1 is any amino acid X1 is a hydrophobic amino acid, such as Ile, Leu, Val, Phe, Tyr, Trp and Met X3 is a hydrophobic amino acid, such as Leu, Ile, Val, Phe, Tyr, Trp and Met X5 is a hydrophobic amino acid, such as Trp, Ile, Val, Phe, Tyr, and Met X2 and X4 are anionic amino acids, preferably each independently is Asp or Glu. The peptide inhibits protein-protein interactions of the Src homology 2 domain-containing phosphatase 2 (SHP2), for the treatment of cancer and RASopathies and as a biomedical research tool.

Abstract: The present invention relates to a chimeric antigen receptor (CAR) molecule containing, from the N-terminus to the C-terminus: a) an extracellular domain and transmembrane domain of human CD19, b) an antigen binding domain, c) a spacer domain, d) a transmembrane domain, and e) a cytoplasmatic domain, preferably wherein the CAR is a CD123 specific CAR (CD123 CAR) and the antigen binding domain includes a VL and/or VH from a monoclonal anti-CD123 antibody, more preferably the antigen binding domain includes a single chain variable fragment (scFv) that specifically binds to CD123.

Abstract: The present invention concerns a short Interfering RNA, which is variant C1858T PTPN22 short interfering RNA duplexes (siRNA), and uses thereof in medical field in the prevention and treatment of autoimmune diseases.

Abstract: A device for the treatment of esophageal stenoses, including at least a body of elongated shape intended to be inserted within the esophagus of a patient, and a tubular sheath mounted around said body to define an interspace between said body and the tubular sheath, wherein it includes a stiffening element accommodated in said interspace and including a plurality of ribs which extend along said interspace.